[Relationship between efficacy of electroacupuncture and electroacupuncture stimulation of different acupoints and different tissue layers of acupoint area in hypotension plus bradycardia rats].
ABSTRACT To explore the relationship between the effect of electroacupuncture (EA) and EA of different layer tissues of the acupoint area and different acupoints in upregulating mean arterial pressure (MAP) and heart rate (HR) in hypotension plus bradycardia rats.
A total of 200 SD rats were used in the present study. Bradycardia plus hypotension model was established by intravenous injection of 0.4% propranolol (0.4 mg/100 g, maintaining dosage 0.025 mg/100 g per minute). EA (2 Hz/15 Hz, 5 mA) was applied to (1) right "Daling" (PC7) and "Jiexi" (ST 41), "Ximen" (PC 4) and "Housanli" (ST 36), "Quze" (PC 3) and "Dubi" (ST 35) which have a similar tissue structure, and are located in the upper and lower limbs and different meridians, and non-acupoint [3 mm left-superior to the "Tianshu" (ST 25)], (2) skin, muscle layer and periosteum part of "Ximen" (PC4), (3) skin, muscle layer and periosteum of "Housanli" (ST36) for 15 min. The HR and MAP were recorded by using a multi-channel physiological signal sampling-processing system.
(1) In comparison with the model group, the percentages of the increased HR and MAP in the "Ximen" (PC4), "Quze" (PC3), "Housanli" (ST 36) and "Jiexi" (ST41) groups, PC 4-skin, PC 4-muscle, PC 4-periosteum, ST 36-skin, ST 36-muscle and ST 36 periosteum groups, and the increased HR in the "Dubi" (ST 35) group were upregulated significantly (P < 0.05, P < 0.01). The percentages of the increased HR and MAP were significantly higher in the "Quze" (PC3) and "Ximen" (PC4) groups than in the "Daling" (PC7) group (P < 0.01), and the increased HR evidently higher in the "Housanli" (ST36) and "Jiexi" (ST41) groups than in the "Dubi" (ST35) group (P < 0.01), suggesting different effects of EA stimulation of different acupoints in the same one meridian. No significant differences were found among the "Ximen" (PC4), "Quze" (PC3), "Housanli" (ST36) and "Jiexi" (ST 41) groups, and between the "Daling" (PC7) and model groups, and between the non-acupoint and model groups in the rising rates of both HR and MAP (P > 0.05). (2) Regarding the effects of EA of different tissue layers in "Ximen" (PC4) and "Housanli" (ST36) areas, the rising rates of HR were markedly higher in the PC 4-skin group than in the "Ximen" (PC4), PC4-muscle and PC 4-periosteum groups (P < 0.01), and considerably higher in the "Housanli" (ST36), ST 36-skin, and ST 36-muscle groups than in ST 36-periosteum group (P < 0.05). The rising rates of MAP were significantly higher in the PC 4-skin and PC 4-muscle groups than in the "Ximen" (PC4) and PC4-periosteum groups (P < 0.01), and considerably higher in the ST36-skin group than in the "Housanli" (ST36), ST36-muscle and ST36-periosteum groups (P < 0.01), suggesting different effects of EA stimulation of different tissue layers in the same one acupoint. No significant differences were found between the "Ximen" (PC 4) and PC 4-muscle groups, among the "Housanli" (ST36), ST36-skin and ST 36-muscle groups in the rising rates of HR, between the "Ximen" (PC 4) and PC4-periosteum groups, and among the "Housanli" (ST36), ST 36-muscle and ST36-periosteum groups in the rising rates of MAP (P > 0.05). (3) The effect of the PC 4-skin group was significantly superior to that of the ST 36-skin group in increasing HR (P < 0.01), and the effect of the PC 4-muscle group was obviously stronger than that of the ST 36-muscle group in raising MAP (P < 0.01), suggesting different therapeutic effects of EA stimulation of the similar tissue in different meridian-acupoints. The effects of the "Ximen"(PC4) and "Housanli" (ST36) groups in raising both HR and MAP, and that of the PC 4-muscle and ST 36-muscle groups in upregulating HR, and that of the PC 4-periosteum and ST 36-periosteum groups in raising MAP were comparable (P > 0.05).
EA of different acupoints of the same one meridian, the similar structure of different meridian acupoints and different tissue layers of the same one acupoint have their own relatively specific effects in upregulating HR and MAP in hypotension plus bradycardia rats.
- SourceAvailable from: Zhishun Liu[Show abstract] [Hide abstract]
ABSTRACT: Acu-point specificity is a key issue in acupuncture. To date there has not been any satisfactory trial which can ratify the specific effect of acupuncture. This trial will evaluate the specific effect of BL33 for mild and moderate benign prostatic hyperplasia (BPH) on the basis of its effectiveness. The non-specific effect will be excluded and the therapeutic effect will be evaluated. This is a double-blinded randomized controlled trial. 100 Patients will be randomly allocated into the treatment group (n = 50) and the control group (n = 50). The treatment group receives needling at BL33 and the control group receives needling at non-point. The needling depth, angle, direction, achievement of De Qi and parameters of electroacupuncture are exactly the same in both groups. The primary outcome measure is reduction of international prostate symptom score (IPSS) at the 6th week and the secondary outcome measures are reduction of bladder residual urine, increase in maximum urinary flow rate at the 6th week and reduction of IPSS at the 18th week. This trial will assess the specific therapeutic effect of electroacupuncture at BL33 for mild and moderate BPH. Protocol Registration System of Clinical Trials.gov NCT01218243.Trials 09/2011; 12:211. · 2.21 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: To evaluate the effects of electroacupuncture (EA) on the International Prostate Symptom Score (IPSS), postvoid residual urine (PVR), and maximum urinary flow rate (Qmax), and explore the difference between EA at acupoints and non-acupoints in patients with moderate to severe benign prostate hyperplasia (BPH). Men with BPH and IPSS ≥8 were enrolled. Participants were randomly allocated to receive EA at acupoint (treatment group, n = 50) and EA at non-acupoint (control group, n = 50). The primary outcome measure includes the change of IPSS at the 6th week and the secondary outcome measures include changes of PVR and Qmax at the 6th week and change of IPSS at the 18th week. 100/192 patients were included. At the 6th week, treatment group patients had a 4.51 (p<0.001) and 4.12 (p<0.001) points greater decline in IPSS than the control group in the intention to treat (ITT) and per-protocol (PP) populations. At the 18th week, a 3.2 points (p = 0.001) greater decline was found in IPSS for the treatment. No significant differences were found between the two groups in Qmax at the 6th week (p = 0.819). No significant difference was observed in PVR (P = 0.35). Acupoint EA at BL 33 had better effects on IPSS, but no difference on PVR and Qmax as compared with non-acupoint EA. The results indicate that EA is effective in improving patient's quality of life and acupoint may have better therapeutic effects than non-acupoints in acupuncture treatments of BPH. ClinicalTrials.gov NCT01218243.PLoS ONE 01/2013; 8(4):e59449. · 3.53 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The theory of acupoint specificity is the basis for elucidating the actions of acupoints as employed in clinical practice. Acupoint specificity has become a focus of attention in international research efforts by scholars in the areas of acupuncture and moxibustion. In 2006, the Chinese Ministry of Science approved and initiated the National Basic Research Program (973 Program), one area of which was entitled Basic Research on Acupoint Specificity Based on Clinical Efficacy. Using such approaches as data mining, evidence-based medicine, clinical epidemiology, neuroimaging, molecular biology, neurophysiology, and metabolomics, fruitful research has been conducted in the form of literature research, clinical assessments, and biological studies. Acupoint specificity has been proved to exist, and it features meridian-propagated, relative, persistent, and conditional effects. Preliminarily investigations have been made into the biological basis for acupoint specificity.Evidence-based Complementary and Alternative Medicine 01/2012; 2012:543943. · 1.72 Impact Factor